

CLAIMS

1. (original) An antibody that specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO: 6.
2. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:7.
3. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:8.
4. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO: 9.
5. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:10.
6. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:11.
7. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:12.
8. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:13.
9. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:14.
10. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:15.
11. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:16.
12. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:17.
13. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:18.
14. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:19.
15. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:20.

16. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:21.
17. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:22.
18. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:23.
19. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:24.
20. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:25.
21. (original) The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:26.
22. (currently amended) The antibody of ~~any one of claims 1-21~~claim 1, wherein the antibody is a monoclonal antibody.
23. (currently amended) The antibody of ~~any one of claims 1-21~~claim 1 wherein the antibody is a humanized or fully human antibody.
24. (currently amended) The antibody of ~~any one of claims 1-23~~claim 1 wherein the one or more epitopes comprise one or more linear epitopes.
25. (currently amended) The antibody of ~~any one of claims 1-23~~claim 1 wherein the one or more epitopes comprise one or more non-linear epitopes.
26. (original) An isolated cell that produces the antibody of claim 22.
27. (currently amended) A pharmaceutical composition comprising the antibody of ~~any one of claims 1-21~~claim 1 and a pharmaceutically acceptable carrier.
28. (original) The pharmaceutical composition of claim 27 wherein the antibody is a monoclonal antibody.
29. (original) The pharmaceutical composition of claim 27 wherein the antibody is a humanized or fully human antibody.
30. (currently amended) The pharmaceutical composition of ~~any one of claims 27-29~~claim 27, further comprising an additional anti-tumor agent.
31. (currently amended) A method for detecting the presence of invasive cells, comprising
- (a) contacting a tissue with an antibody according to ~~any one of claims 1-21~~claim 1 to form an immunocomplex between the antibody and a laminin 5 λ 2

epitope in the tissue; and

(b) detecting formation of the immunocomplex, wherein the formation of the immunocomplex correlates with the presence of invasive cells in the tissue.

32. (original) The method of claim 31 wherein the tumor tissue comprises a carcinoma.

33. (currently amended) A method for inhibiting tumor growth, comprising administering to a patient with a tumor an amount effective to inhibit tumor growth of an antibody according to ~~any one of claims 1-21~~claim 1.

34. (original) The method of claim 33 wherein the tumor comprises a carcinoma.

35. (original) The method of claim 33 wherein the method is used in combination with one or more of the following treatments:

- (a) primary surgery for removing one or more tumors;
- (b) secondary cytoreductive surgery;
- (c) palliative secondary surgery;
- (d) radiation therapy; and
- (e) chemotherapy.

36. (currently amended) A method for inhibiting tumor metastasis, comprising administering to a patient with a tumor an amount effective to inhibit tumor metastasis of an antibody according to ~~any one of claims 1-21~~claim 1.

37. (original) The method of claim 36 wherein the tumor comprises a carcinoma.

38. (original) The method of claim 36 wherein the method is used in combination with one or more of the following treatments:

- (a) primary surgery for removing one or more tumors;
- (b) secondary cytoreductive surgery;
- (c) palliative secondary surgery;
- (d) radiation therapy; and
- (e) chemotherapy.

39. (currently amended) The method of ~~any one of claims 31-38~~claim 31 wherein the antibody is a monoclonal antibody.

40. (currently amended) The method of ~~any one of claims 31-38~~claim 31 wherein the antibody is a humanized or fully human antibody.

41. (currently amended) Use of an antibody according to ~~any one of claims 1-21~~claim 1 for the preparation of a medicament for inhibiting tumor metastasis.

42. (currently amended) Use of an antibody according to ~~any one of claims 1-21~~

claim 1 for the preparation of a medicament for inhibiting tumor growth.

43. (currently amended) The use of claim 41 ~~or 42~~ wherein the antibody is a monoclonal antibody.

44. (currently amended) The use of claim 41 ~~or 42~~ wherein the antibody is a humanized or fully human antibody.

45. (currently amended) The use of ~~any one of claims 41-44~~**claim 41** wherein the tumor comprises a carcinoma.

46. (currently amended) The use of ~~any one of claims 41-44~~**claim 41** wherein the medicament is prepared for use in combination with one or more of the following treatments:

- (a) primary surgery for removing one or more tumors;
- (b) secondary cytoreductive surgery;
- (c) palliative secondary surgery;
- (d) radiation therapy; and
- (e) chemotherapy.

47. (original) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 6-26.